Oded S. Lieberman
PhD, MBA – CEO
Dr. Lieberman has 25 years international experience in corporate leadership, technology development and the successful launch and commercialization of diagnostics, drugs and medical devices. He has served as CEO of NeuroDerm since December 2007 and was Chairman of the Board between 2005 and 2013. He previously held the positions of CEO and President of Proteologics Ltd., and Vice President of Surgical Products at Omrix Biopharmaceuticals Ltd. (later floated on NASDAQ (OMRX) and acquired by J&J). Prior to Omrix, Dr. Lieberman held senior management positions at Octapharma AG and Boehringer Mannheim GmbH (later Roche Diagnostics) including marketing and business development positions and, in addition, served as chairman and/or a member of the board of several health care companies.
Dr. Lieberman has a PhD in Biology from the Hebrew University of Jerusalem and an MBA from INSEAD (Fontainebleau).
MA – COO
Ms. Yardeni has more than 18 years of experience in the pharmaceutical industry in various capacities, gained within large pharmaceutical companies and CROs. She was previously with Teva Pharmaceutical Industries, most recently as VP, Head of Global Clinical Operation, Global R&D where she was responsible for the operational execution of global development programs across all indications from Phase I to regulatory approval and commercialization. She was responsible for a budget of several hundreds of millions of dollars and her responsibilities included direct oversight of 150 clinical trials annually. From 1999 to 2011, Ms. Yardeni held positions of increasing responsibility in the area of Biometrics at Teva, including six years of managing the Global Data Management Center of Excellence, where she led the strategic planning and execution of data management outsourcing and off-shoring, as well as the post-acquisition integration processes for various biometrics functions. She received both her B.A. in Statistics and M.A. in Applied Statistics from Haifa University.
MD, MBA – CMO
Dr. Oren has 20 years of international pharma experience, mainly at Teva Pharmaceuticals, where she served as Medical Director. She was responsible for the clinical development and marketing of innovative drugs in CNS and specifically in Parkinson’s disease. Dr. Oren has served as VP Clinical and Regulatory Affairs since September 2008. She also serves as a member of the investment committee and advisory board of New Generation Technology (NGT), a technology incubator, and as a director of MedWell Laboratories Ltd.
Dr. Oren holds an MD from the Sackler School of Medicine, Tel Aviv University and an MBA from the Interdisciplinary Center, Herzliya.
PhD, DVM – CSO
Dr. Yacoby-Zeevi has 20 years experience in leading research and development programs and GLP compliant pre-clinical development of numerous small molecule drugs and biologicals in various indications, including CNS diseases, for the pharmaceutical and biotech industry. Dr. Yacoby-Zeevi has been leading NeuroDerm’s R&D since 2007. Prior to that, she served as Chief Science Officer at Harlan Biotech Israel Ltd., and R&D team leader at Insight Biopharmaceuticals Ltd. She is the author of more than 15 patents.
Dr. Yacoby-Zeevi holds a Doctorate in Veterinary Medicine from the Koret School of Veterinary Medicine of the Hebrew University of Jerusalem and a PhD in Microbiology and Immunology from the Ben-Gurion University of the Negev.
PhD – VP CMC & QA
Dr. Cohen-Vered has more than 20 years experience in the pharmaceutical industry. She has served as Head of Chemistry, Manufacturing and Controls since August 2008. Previously she was employed at Teva Pharmaceuticals Ltd. where she served in various positions including Head of Sterile Dosage Form development and team leader in the Innovative R&D.
Sharon holds a PhD in Biochemistry from Tel Aviv University.
BSc – VP Devices
Mr. Shor has 18 years of experience in the development, registration, production and commercialization of medical devices. Prior to joining the company, Mr. Shor was the Chief Executive Officer of PerfAction Technologies, a company that develops technologies and medical devices for drug delivery, where he led the company from the R&D stage to global commercialization. In this capacity From 2009 to 2013, Mr. Shor was COO of PerfAction Technologies, where he led multi-disciplinary R&D teams that integrated mechanics, electronics, pneumatics, and software development. From 2003 to 2009, he held positions of increasing responsibility at GI View, a company focused on developing a new generation of endoscopy products for gastrointestinal applications based on unique visualization and self-propelled pneumatic intubation technology. These positions included Mechanical & System Manager, VP of R&D & COO. Previously Mr. Shor held positions in Mechanical Engineering at Nova and Elan Medical, where he took part in developing a wearable drug delivery pump. He received his B.Sc. in Mechanical Engineering from Tel Aviv University.
CPA, LLM – CFO
Mr. Golan has served as VP Finance since January 2014. Previously, from 2008 to 2012, Mr. Golan served as CFO of KCS Ltd., a software company that provides GRC solutions. From 2005 to 2008, he served as VP Finance of GI View Ltd., a medical device start up that develops a screening solution for the colon. Prior to this, Mr. Golan served as a controller at NASDAQ listed On Track Innovations Ltd., a leading contactless smart card solution provider where he had a pivotal role in all corporate financial matters, including company’s registration on NASDAQ, as well as in the implementation of the Sarbanes-Oxley act. Prior to this he served as a senior consultant at Pricewaterhouse Coopers LLP (PWC).
Mr. Golan holds a BA degree in Business and Accounting from the Israeli College of Management and an LLM from Bar-Ilan University. Mr. Golan has been a licensed CPA since 2002.
Revital Mandil Levin
PhD, MBA – VP Corporate Development
Dr. Mandil-Levin has more than 15 years experience in biotech startups and product development in the pharmaceutical industry. Revital has served as Head of Business Development since January 2014. From 2004 -2013 she served as VP Business Development and Portfolio development at HealOr Ltd., a clinical stage company that developed innovative topical drugs for chronic wounds and other skin diseases. Prior to that, she served as Business Development Manager at Proteologics Ltd.
Dr. Mandil Levin holds a PhD in Biochemistry from Bar-Ilan University and an MBA from the Israeli College of Management School of Business.
BSc – VP Regulatory Affairs
Ms. Mesika has more than 25 years of R&D and Regulatory experience in the pharmaceutical industry working for both medium and large pharmaceutical companies. During her six-year tenure at Teva Pharmaceutical Industries, Ms. Mesika was the Global RA leader for biosimilar products in Global R&D and Head of Regulatory Affairs for Specialty Products in Growth Markets Region. She was responsible for setting the regulatory strategy for development and registration of innovative drugs, biologics and combination products from various therapeutic areas, including CNS, Pain, Oncology, and Respiratory. Ms. Mesika holds a BSc in Biology from the Hebrew University in Jerusalem.
MSc – VP Human Resources
Ms. Nahmany has over 20 years of experience in organizational transformation. Her work is focused on defining organizational strategy, implementing change management, and building leadership teams, with an emphasis on global development. Ms. Nahmany has advised companies in the pharmaceutical, biotech and communications sectors, including leading global companies such as Teva Pharmaceutical Industries. She has also served in various consultancy positions at PricewaterhouseCoopers and McKenzie, and was COO of White Water, focused on smart water network management software.
Ms. Nahmany holds an MSc in Management and Group Dynamics from Tel Aviv University.
BSc, MBA – VP Commercial, US
Mr. Udell has more than 18 years of commercial and leadership experience in the biotech and pharmaceutical industry. In addition to consulting for several biotech companies, he has held several leadership roles, including Vice President of Marketing at Clinical Data Inc., a biotech company acquired by Forest Laboratories for $1.2 billion. While at Clinical Data, Mr. Udell was responsible for all commercial and launch-related activities as the company moved from a late stage R&D company through FDA approval of the novel antidepressant, Viibryd®. He began his pharmaceutical career at Purdue Pharma and held a variety of sales and marketing positions, including brand business leader, managing a multifunctional team for a blockbuster pain medication. Mr. Udell holds a BSc from Lehigh University and an MBA from the University of Connecticut.